Bar Harbor, ME
The primary research goals of the Lutz lab involve developing preclinical mouse models of neurodegeneration to test therapeutics and inform clinical trials.
1997
Ph.D., biochemistry
University of Maine, Orono, ME
1990
B.S., biochemistry
The University of Pittsburgh, Pittsburgh, PA
2011-
Director, Repository, and Research Scientist, Genetic Resource Science, The Jackson Laboratory, Bar Harbor, ME
2008-2011
Associate Director and Research Scientist, Genetic Resource Science, The Jackson Laboratory, Bar Harbor, ME
2004-2008
Mouse Repository Operations Manager and Associate Research Scientist, The Jackson Laboratory, Bar Harbor, ME
1998-2004
Senior Scientific Curator, Mouse Genome Informatics, The Jackson Laboratory, Bar Harbor, ME
1996-1998
Postdoctoral Associate, Laboratory of Dr. David Hosford, Duke University, Durham North Carolina
1993-1996
Predoctoral Associate, Laboratory of Dr. Wayne Frankel, The Jackson Laboratory, Bar Harbor, ME
1991-1993
Senior Research Assistant, Laboratory of Dr. Wayne Frankel, The Jackson Laboratory, Bar Harbor, ME
1990-1991
Research Assistant, Laboratory of Dr. Benjamin Taylor, The Jackson Laboratory, Bar Harbor, ME
1987-1990
Research Technician, Laboratory of Dr. Mary Edmonds, The University of Pittsburgh, Pittsburgh, PA
The Search Magazine Article
February 28, 2017
A mouse model of spinal muscular atrophy developed at The Jackson Laboratory lay the foundation for the successful clinical trials of a new SMA drug, Spinraza.
Most cases of amyotrophic lateral sclerosis (ALS) are sporadic, meaning that there is no family history of the disease.
Press Release
October 14, 2015
In work involving several new generations of mouse model development, Jackson Laboratory (JAX) researchers have tested a therapeutic intervention for spinal muscular atrophy (SMA) that restores some function lost due to a mutation in one gene (SMN1) and amplifies the levels of protective genes (SMN2). Moreover, unlike current interventions, the therapy appears to work after symptoms of SMA have already appeared, and may not need to be administered directly into the central nervous system.
Two 2011 studies demonstrate that restoring or increasing spinal motor neuron (SMN) protein alleviates or even reverses disease in spinal muscular atrophy (SMA) mouse models.
The Search Magazine Article
January 17, 2017
Australian researcher Sarah Stephenson wanted to fast-track her research of Parkinson's disease, so she shuffled the genetic deck using a new experimental platform at The Jackson Laboratory.
eNews
December 12, 2014
Scientists are rapidly engineering mice that model these genetic lesions which will be critical for understanding pathogenesis of these diseases.
A novel, allelic series of spinal muscular atrophy (SMA) mouse models have been created that differ in SMN expression levels and SMA-related disease severity.
The Search Magazine Article
July 01, 2011
Huntington's disease hasn't stopped Cathy Alley from pursuing her passion for live music or supporting the search for cures for her disease.